In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Start-Up Previews (11/2008)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "In Immunotherapy, Finally Time for T Cells?," features profiles of Adaptimmune, Altor BioScience, and Cell Medica. Plus these Start-Ups Across Health Care: Adnavance Technologies, Amplyx Pharmaceuticals, IlluminOss Medical, and KM Medical.

You may also be interested in...

Adnavance Technologies Inc.

Even though mortality rates double each day an MRSA infection remains untreated, most hospitals have to outsource diagnostics test to off-site labs, losing precious treatment time. Adnavance Technologies hopes to change this. The company's ADNAstat amplification-free technology enalbes rapid detection of MRSA DNA on-site at any hospital.

KM Medical Ltd.

KM Medical was formed to develop a revolutionary neonatal resuscitator to meet the needs of an underserved market. KM Medical's offering is an automatic, hand-held resuscitator with transport ventilator capability designed for controlled delivery of the small volumes of air that neonates require and a display technology that verifies that delivery.

Amplyx Pharmaceuticals Inc.

Other companies' disappointments could turn out to be blessings for Amplyx Pharmaceuticals. The start-up thinks it has a solution for ADME problems that derail candidates in clinical trials or that lead to side effects and reduced efficacy in marketed drugs. Amplyx believes it can improve problematic small-molecule drugs by extending their half-life without making the compounds too big to be delivered orally.

Related Content

Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts